VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX)

Historical Holders from Q1 2014 to Q3 2025

Symbol
VRTX on Nasdaq
Type / Class
Equity / Common Stock
Shares outstanding
257M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
232M
Holdings value
$90.6B
% of all portfolios
0.037%
Grand Portfolio weight change
-0.006%
Number of holders
1489
Number of buys
669
Number of sells
-761
Average Value change %
0%
Average buys %
+0.006%
Average sells %
-0.008%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Capital World Investors 11.2% $14.5B 28.7M Capital World Investors 31 Dec 2024
Capital Research Global Investors 5.7% $7.32B 14.5M Capital Research Global Investors 31 Mar 2025
FMR LLC 3.6% $4.64B 9.22M FMR LLC 31 Dec 2024

Institutional Holders of VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 232M $90.6B -$3.69B $391.64 1,489
2025 Q2 241M $107B +$1.86B $445.20 1,543
2025 Q1 237M $115B +$570M $484.82 1,597
2024 Q4 236M $95.1B +$124M $402.70 1,542
2024 Q3 234M $109B -$109M $465.08 1,532
2024 Q2 234M $110B +$127M $468.72 1,538
2024 Q1 234M $97.6B -$352M $418.01 1,481
2023 Q4 235M $95.5B -$282M $406.89 1,430
2023 Q3 235M $81.8B -$492M $347.74 1,268
2023 Q2 237M $83.2B -$330M $351.91 1,270
2023 Q1 237M $74.8B +$552M $315.07 1,191
2022 Q4 237M $68.5B +$69.2M $288.78 1,206
2022 Q3 237M $68.7B +$746M $289.54 1,108
2022 Q2 234M $65.9B +$619M $281.79 1,093
2022 Q1 234M $60.9B +$1.12B $260.97 1,050
2021 Q4 230M $50.4B -$237M $219.60 1,015
2021 Q3 231M $41.8B -$223M $181.39 920
2021 Q2 232M $46.7B -$412M $201.63 961
2021 Q1 236M $50.6B -$677M $214.89 983
2020 Q4 239M $56.4B -$908M $236.34 952
2020 Q3 242M $65.8B -$146M $272.12 931
2020 Q2 242M $70.3B -$453M $290.31 949
2020 Q1 244M $58.1B +$197M $237.95 842
2019 Q4 243M $53.3B -$548M $218.95 801
2019 Q3 246M $41.6B +$11.1M $169.42 696
2019 Q2 246M $45B +$698M $183.38 706
2019 Q1 245M $45.1B +$339M $183.95 727
2018 Q4 243M $40.3B +$326M $165.71 690
2018 Q3 241M $46.5B +$73.1M $192.74 687
2018 Q2 241M $41B +$46.7M $169.96 682
2018 Q1 241M $39.2B +$165M $162.98 674
2017 Q4 240M $35.9B +$289M $149.86 637
2017 Q3 238M $36.1B +$313M $152.04 605
2017 Q2 236M $30.4B +$78.1M $128.87 569
2017 Q1 236M $25.8B +$2.17B $109.35 512
2016 Q4 236M $17.4B -$346M $73.67 470
2016 Q3 241M $21B +$86.2M $87.21 480
2016 Q2 240M $20.6B +$255M $86.02 473
2016 Q1 237M $18.8B -$181M $79.49 487
2015 Q4 235M $29.5B -$17.3M $125.83 510
2015 Q3 235M $24.5B +$667M $104.14 487
2015 Q2 230M $28.4B -$407M $123.48 496
2015 Q1 233M $27.5B +$443M $117.97 471
2014 Q4 230M $27.3B -$489M $118.80 467
2014 Q3 233M $26.2B +$764M $112.31 424
2014 Q2 227M $21.5B +$278M $94.68 405
2014 Q1 223M $15.8B +$100M $70.72 390